Department of Pharmaceutical Quality Assurance, ISF College Pharmacy, Moga, India.
Department of Pharmaceutics, ISF College Pharmacy, Moga, India.
J Drug Target. 2024 Jun;32(5):510-528. doi: 10.1080/1061186X.2024.2333866. Epub 2024 Apr 3.
Aptamers, a novel type of targeted ligand used in drug delivery, have quickly gained popularity due to their high target specificity and affinity. Different aptamer-mediated drug delivery systems, such as aptamer-drug conjugate (ApDC), aptamer-siRNA, and aptamer-functionalised nanoparticle systems, are currently being developed for the successful treatment of cancer based on the excellent properties of aptamers. These systems can decrease potential toxicity and enhance therapeutic efficacy by targeting the drug moiety. In this review, we provide an overview of recent developments in aptamer-mediated delivery systems for cancer therapy, specifically for breast cancer, and talk about the potential applications and current issues of novel aptamer-based techniques. This study in aptamer technology for breast cancer therapy highlights key aptamers targeting well-established biomarkers such as HER2, oestrogen receptor, and progesterone receptor. Additionally, we explore the potential of aptamers in overcoming various challenges such as drug resistance and improving the delivery of therapeutic agents. This review aims to provide a deeper understanding of the present aptamer-based targeted delivery applications through in-depth analysis to increase efficacy and create new therapeutic approaches that may ultimately lead to better treatment outcomes for cancer patients.
适配体是一种新型的靶向配体，用于药物递送，由于其高靶特异性和亲和力而迅速流行。不同的适配体介导的药物递送系统，如适配体-药物偶联物（ApDC）、适配体-siRNA 和适配体功能化纳米粒子系统，目前正在基于适配体的优异特性开发用于成功治疗癌症，通过靶向药物部分来降低潜在毒性并提高治疗效果。在这篇综述中，我们概述了用于癌症治疗的适配体介导的递药系统的最新进展，特别是针对乳腺癌，并讨论了新型基于适配体的技术的潜在应用和当前问题。本研究强调了针对乳腺癌治疗的关键适配体，这些适配体针对已确立的生物标志物，如 HER2、雌激素受体和孕激素受体。此外，我们还探讨了适配体在克服各种挑战（如耐药性）和改善治疗剂的递送上的潜力。本综述旨在通过深入分析，提供对基于适配体的靶向递药应用的更深入理解，以提高疗效并创造新的治疗方法，最终可能为癌症患者带来更好的治疗效果。
